ES8207428A1 - Procedimiento para la preparacion de una nueva forma de ac- cion retardada a base de dipiridamol - Google Patents
Procedimiento para la preparacion de una nueva forma de ac- cion retardada a base de dipiridamolInfo
- Publication number
- ES8207428A1 ES8207428A1 ES498393A ES498393A ES8207428A1 ES 8207428 A1 ES8207428 A1 ES 8207428A1 ES 498393 A ES498393 A ES 498393A ES 498393 A ES498393 A ES 498393A ES 8207428 A1 ES8207428 A1 ES 8207428A1
- Authority
- ES
- Spain
- Prior art keywords
- weight
- preparation
- percent
- coating
- forms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
PROCEDIMIENTO PARA LA PREPARACION DE UNA FORMA DE ACCION RETARDADA A BASE DE DIPIRIDAMOL. A TEMPERATURA AMBIENTE SE APLICA, SOBRE NUCLEOS INICIADORES QUE CONSTAN DE UN ACIDO O DE UNA SUSTANCIA ACIDA Y EN PRESENCIA DE UN AGENTE ADHESIVO LIQUIDO, DIPIRIDAMOL EN FORMA DE POLVO O FINALMENTE CRISTALIZADO HASTA ALCANZAR UN VAL DE SUSTANCIA ACIDA POR UN MOL DE DIPIRIDAMOL. SE EMPLEA UN GRANULADOR DE CAPA FLUIDIFICADA PARA FORMAR GRANULOS QUE SE ROCIAN DE NUEVO CON ADHESIVO LIQUIDO Y SE INCORPORA LA CANTIDAD RESTANTE DE DIPIRIDAMOL. SE SECAN LOS GRANULOS Y SE ROCIAN DE BARNIZ SOLUBLE.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19803000979 DE3000979A1 (de) | 1980-01-12 | 1980-01-12 | Neue dipyridamol-retardformen und verfahren zu ihrer herstellung |
Publications (2)
Publication Number | Publication Date |
---|---|
ES498393A0 ES498393A0 (es) | 1982-09-16 |
ES8207428A1 true ES8207428A1 (es) | 1982-09-16 |
Family
ID=6091926
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES498393A Expired ES8207428A1 (es) | 1980-01-12 | 1981-01-09 | Procedimiento para la preparacion de una nueva forma de ac- cion retardada a base de dipiridamol |
Country Status (32)
Country | Link |
---|---|
US (1) | US4367217A (es) |
EP (1) | EP0032562B1 (es) |
JP (1) | JPS56103111A (es) |
AR (1) | AR221983A1 (es) |
AT (1) | ATE6585T1 (es) |
AU (1) | AU539618B2 (es) |
CA (1) | CA1148084A (es) |
CS (1) | CS232713B2 (es) |
DD (1) | DD156943A5 (es) |
DE (2) | DE3000979A1 (es) |
DK (1) | DK158539C (es) |
ES (1) | ES8207428A1 (es) |
FI (1) | FI78835C (es) |
GB (1) | GB2067073B (es) |
GR (1) | GR73102B (es) |
HK (1) | HK62184A (es) |
HU (1) | HU184366B (es) |
IE (1) | IE50807B1 (es) |
IL (1) | IL61887A (es) |
IN (1) | IN155158B (es) |
KE (1) | KE3402A (es) |
MA (1) | MA19040A1 (es) |
MY (1) | MY8500559A (es) |
NO (1) | NO157369C (es) |
NZ (1) | NZ195994A (es) |
OA (1) | OA06720A (es) |
PH (1) | PH17063A (es) |
PL (1) | PL129290B1 (es) |
PT (1) | PT72330B (es) |
SG (1) | SG28184G (es) |
YU (1) | YU42549B (es) |
ZA (1) | ZA811661B (es) |
Families Citing this family (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2470599A1 (fr) * | 1979-12-07 | 1981-06-12 | Panoz Donald | Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus |
DE3264867D1 (en) * | 1981-04-27 | 1985-08-29 | Haessle Ab | New pharmaceutical preparation |
DE3124090A1 (de) * | 1981-06-19 | 1983-01-05 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue orale dipyridamolformen |
DE3126703A1 (de) | 1981-07-07 | 1983-01-27 | Dr. Karl Thomae Gmbh, 7950 Biberach | Bromhexin-retardform und verfahren zu ihrer herstellung |
IE54171B1 (en) * | 1982-06-22 | 1989-07-05 | Univ Glasgow | Device for introducing nutrients and/or therapeutic materials into ruminant animals |
US4704284A (en) * | 1982-08-12 | 1987-11-03 | Pfizer Inc. | Long-acting matrix tablet formulations |
DE3237575A1 (de) * | 1982-10-09 | 1984-04-12 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue orale mopidamolformen |
DK58983D0 (da) * | 1983-02-11 | 1983-02-11 | Leo Pharm Prod Ltd | Farmaceutisk praeparat |
DE3306250A1 (de) * | 1983-02-23 | 1984-08-23 | Basf Ag, 6700 Ludwigshafen | Sphaerische einkristalle fuer pharmazeutische zwecke |
IE55745B1 (en) * | 1983-04-06 | 1991-01-02 | Elan Corp Plc | Sustained absorption pharmaceutical composition |
KR880002139B1 (ko) * | 1983-04-08 | 1988-10-17 | 베링거 인겔하임 리미티드 | 경구 투여용 정제의 제조방법 |
JPS6051106A (ja) * | 1983-08-31 | 1985-03-22 | Yamanouchi Pharmaceut Co Ltd | 塩酸アモスラロ−ル持続性製剤 |
IE56459B1 (en) * | 1983-12-21 | 1991-08-14 | Elan Corp Ltd | Controlled absorption pharmaceutical formulation |
GB8414221D0 (en) * | 1984-06-04 | 1984-07-11 | Sterwin Ag | Unit dosage form |
GB8414220D0 (en) * | 1984-06-04 | 1984-07-11 | Sterwin Ag | Medicaments in unit dose form |
US4867984A (en) * | 1984-11-06 | 1989-09-19 | Nagin K. Patel | Drug in bead form and process for preparing same |
DE3627423A1 (de) * | 1986-08-13 | 1988-02-18 | Thomae Gmbh Dr K | Arzneimittel enthaltend dipyridamol oder mopidamol und o-acetylsalicylsaeure bzw. deren physiologisch vertraegliche salze, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung der thrombusbildung |
SE460947B (sv) * | 1986-08-26 | 1989-12-11 | Lejus Medical Ab | En multiple-unit-dos komposition av l-dopa |
WO1988002629A1 (en) * | 1986-10-16 | 1988-04-21 | American Health Products Corporation | 2',3'-didesoxyadenosine composition |
US5075109A (en) * | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
US6024983A (en) * | 1986-10-24 | 2000-02-15 | Southern Research Institute | Composition for delivering bioactive agents for immune response and its preparation |
US4800087A (en) * | 1986-11-24 | 1989-01-24 | Mehta Atul M | Taste-masked pharmaceutical compositions |
IL84599A0 (en) * | 1986-12-09 | 1988-04-29 | Byk Gulden Lomberg Chem Fab | Pharmaceutical composition containing urapidil and process for the preparation thereof |
DE3812799A1 (de) * | 1988-04-16 | 1989-10-26 | Sanol Arznei Schwarz Gmbh | Oral zu verabreichende pharmazeutische zubereitung mit kontrollierter wirkstofffreisetzung und verfahren zu deren herstellung |
GB8813032D0 (en) * | 1988-06-02 | 1988-07-06 | Boehringer Ingelheim Int | Antiviral pharmaceutical composition |
US5196203A (en) * | 1989-01-06 | 1993-03-23 | F. H. Faulding & Co. Limited | Theophylline dosage form |
US5202128A (en) * | 1989-01-06 | 1993-04-13 | F. H. Faulding & Co. Limited | Sustained release pharmaceutical composition |
US5084278A (en) * | 1989-06-02 | 1992-01-28 | Nortec Development Associates, Inc. | Taste-masked pharmaceutical compositions |
AT397345B (de) * | 1990-04-04 | 1994-03-25 | Chemiefaser Lenzing Ag | Pharmazeutisches präparat mit verzögerter wirkstofffreisetzung auf basis von hemicellulosen |
NZ242806A (en) * | 1991-05-20 | 1994-01-26 | Marion Laboratories Inc | Multi-layered acid-containing coated drug beads. |
DE69331906T2 (de) * | 1992-08-05 | 2002-12-19 | Faulding F H & Co Ltd | Granulierte pharmazeutische zusammensetzung |
US6818229B1 (en) | 1993-09-20 | 2004-11-16 | Kos Pharmaceuticals, Inc. | Intermediate release nicotinic acid compositions for treating hyperlipidemia |
US6676967B1 (en) * | 1993-09-20 | 2004-01-13 | Kos Pharmaceuticals, Inc. | Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia |
US20060263428A1 (en) * | 1993-09-20 | 2006-11-23 | Eugenio Cefali | Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristics |
US6746691B2 (en) | 1993-09-20 | 2004-06-08 | Kos Pharmaceuticals, Inc. | Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics |
US6080428A (en) | 1993-09-20 | 2000-06-27 | Bova; David J. | Nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
US6129930A (en) * | 1993-09-20 | 2000-10-10 | Bova; David J. | Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night |
US20060067999A1 (en) * | 1996-03-25 | 2006-03-30 | Wyeth | Extended release formulation |
JP2000159692A (ja) * | 1998-09-25 | 2000-06-13 | Sankyo Co Ltd | HMG―CoAレダクタ―ゼ阻害薬含有製剤 |
WO2000018396A1 (fr) * | 1998-09-25 | 2000-04-06 | Sankyo Company, Limited | PREPARATIONS A BASE D'INHIBITEUR DE HMG-CoA |
CA2383220C (en) | 1999-09-02 | 2009-11-03 | Nostrum Pharmaceuticals, Inc. | Controlled release pellet formulation |
EP1223937A2 (en) * | 1999-10-07 | 2002-07-24 | Novaneuron Inc. | Gene necessary for striatal function, uses thereof, and compounds for modulating same |
EP1093814A1 (en) * | 1999-10-22 | 2001-04-25 | Boehringer Ingelheim Pharma KG | Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders |
DE60128215T2 (de) | 2000-04-20 | 2008-01-10 | Novartis Ag | Beschichtungszusammensetzung zur geschmacksmaskierung |
US7064130B2 (en) * | 2001-04-20 | 2006-06-20 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of radical-scavenging compounds for treatment and prevention of NO-dependent microcirculation disorders |
US7183410B2 (en) * | 2001-08-02 | 2007-02-27 | Bidachem S.P.A. | Stable polymorph of flibanserin |
US20030060475A1 (en) * | 2001-08-10 | 2003-03-27 | Boehringer Ingelheim Pharma Kg | Method of using flibanserin for neuroprotection |
NZ532310A (en) | 2001-10-05 | 2007-02-23 | Combinatorx Inc | Combinations comprising a tetra-substituted pyrimidopyrimidine and a corticosteroid for the treatment of immunoinflammatory disorders |
DE10149674A1 (de) | 2001-10-09 | 2003-04-24 | Apogepha Arzneimittel Gmbh | Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung |
US10675280B2 (en) | 2001-10-20 | 2020-06-09 | Sprout Pharmaceuticals, Inc. | Treating sexual desire disorders with flibanserin |
UA78974C2 (en) * | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
US20030181488A1 (en) | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof |
US20040048877A1 (en) * | 2002-05-22 | 2004-03-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions containing flibanserin |
JP2006516593A (ja) * | 2003-02-07 | 2006-07-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Mmp−9依存性疾患の治療及び予防のためのジピリダモール又はモピダモールの使用 |
DE10306179A1 (de) | 2003-02-13 | 2004-08-26 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von Dipyridamol in Kombination mit Acetylsalicylsäure und einem Angiotensin II-Antagonisten zur Schlaganfall-Prophylaxe |
WO2004093881A2 (en) | 2003-04-24 | 2004-11-04 | Boehringer Ingelheim International Gmbh | Use of dipyridamole or mopidamole for treatment and prevention of thrombo-embolic diseases and disorders caused by excessive formation of thrombin and/or by elevated expression of thrombin receptors |
DE10339862A1 (de) * | 2003-08-29 | 2005-03-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel |
US20050112199A1 (en) * | 2003-09-24 | 2005-05-26 | Mahesh Padval | Therapeutic regimens for administering drug combinations |
TW200517114A (en) | 2003-10-15 | 2005-06-01 | Combinatorx Inc | Methods and reagents for the treatment of immunoinflammatory disorders |
US20050239798A1 (en) * | 2004-04-22 | 2005-10-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | Method for the treatment of premenstrual and other female sexual disorders |
WO2005113006A2 (en) * | 2004-05-13 | 2005-12-01 | Boehringer Ingelheim International Gmbh | Use of dipyridamole for treatment of resistance to platelet inhibitors |
US20060025420A1 (en) * | 2004-07-30 | 2006-02-02 | Boehringer Ingelheimn International GmbH | Pharmaceutical compositions for the treatment of female sexual disorders |
JP2008531714A (ja) * | 2005-03-04 | 2008-08-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 不安障害の治療用及び/又は予防用の医薬組成物 |
WO2006096439A2 (en) * | 2005-03-04 | 2006-09-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases |
RU2403033C2 (ru) | 2005-03-22 | 2010-11-10 | Лозан Фарма Гмбх | Солюбилизированный ибупрофен |
EP1888071A1 (en) * | 2005-05-19 | 2008-02-20 | Boehringer Ingelheim International GmbH | Method for the treatment of drug-induced sexual dysfunction |
US8227476B2 (en) | 2005-08-03 | 2012-07-24 | Sprout Pharmaceuticals, Inc. | Use of flibanserin in the treatment of obesity |
US20070087056A1 (en) * | 2005-08-09 | 2007-04-19 | Claudia Guthmann | Pharmaceutical form with sustained pH-independent active ingredient release for active ingredients having strong pH-dependent solubility |
CA2619035A1 (en) * | 2005-08-22 | 2007-03-01 | Novartis Ag | Pharmaceutical compositions |
GB0517204D0 (en) * | 2005-08-22 | 2005-09-28 | Novartis Ag | Organic compounds |
CA2626134C (en) * | 2005-10-29 | 2013-12-24 | Boehringer Ingelheim International Gmbh | Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders |
US20070105869A1 (en) * | 2005-11-08 | 2007-05-10 | Stephane Pollentier | Use of flibanserin for the treatment of pre-menopausal sexual desire disorders |
WO2007090082A2 (en) * | 2006-01-27 | 2007-08-09 | Eurand, Inc. | Drug delivery systems comprising weakly basic selective serotonin 5-ht3 blocking agent and organic acids |
KR20140088230A (ko) | 2006-01-27 | 2014-07-09 | 앱탈리스 파마테크, 인코포레이티드 | 약 염기성 약물과 유기산을 포함하는 약물 전달 시스템 |
AU2006337643A1 (en) * | 2006-02-09 | 2007-08-16 | Teva Pharmaceutical Industries Ltd. | Dipyridamole extended-release formulations and process for preparing same |
NZ573382A (en) * | 2006-05-09 | 2012-02-24 | Boehringer Ingelheim Int | Use of flibanserin for the treatment of post-menopausal sexual desire disorders |
US20080003213A1 (en) * | 2006-05-22 | 2008-01-03 | Jan Lessem | Methods and compositions for the treatment of diseases or conditions associated with increased C-reactive protein, interleukin-6, or interferon-gamma levels |
WO2008000760A1 (en) * | 2006-06-30 | 2008-01-03 | Boehringer Ingelheim International Gmbh | Flibanserin for the treatment of urinary incontinence and related diseases |
EP2043648A1 (en) * | 2006-07-14 | 2009-04-08 | Boehringer Ingelheim International GmbH | Use of flibanserin for the treatment of sexual disorders in females |
CL2007002214A1 (es) | 2006-08-14 | 2008-03-07 | Boehringer Ingelheim Int | Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp |
EP2054041A2 (en) | 2006-08-14 | 2009-05-06 | Boehringer Ingelheim International GmbH | Formulations of flibanserin and method for manufacturing the same |
AR062321A1 (es) * | 2006-08-25 | 2008-10-29 | Boehringer Ingelheim Int | Sistema de liberacion controlada y metodo para fabricarlo |
EP1894561A1 (en) * | 2006-08-30 | 2008-03-05 | Dr. Reddy's Laboratories Ltd. | Dipyridamole pharmaceutical compositions |
JP2010522714A (ja) * | 2007-03-28 | 2010-07-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規な医薬組成物 |
CL2008002693A1 (es) * | 2007-09-12 | 2009-10-16 | Boehringer Ingelheim Int | Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad |
CA2737131A1 (en) * | 2007-09-19 | 2009-03-26 | Zalicus Inc. | Therapeutic regimens for the treatment of immunoinflammatory disorders |
JP2011506607A (ja) * | 2007-12-17 | 2011-03-03 | ザリカス インコーポレイティッド | 免疫炎症性障害の処置のための治療法 |
US8377474B2 (en) | 2007-12-28 | 2013-02-19 | Impax Laboratories, Inc. | Controlled release formulations of levodopa and uses thereof |
WO2009097156A1 (en) * | 2008-02-01 | 2009-08-06 | Barr Laboratories, Inc. | Pharmaceutical capsules comprising extended release dipyridamole pellets |
US8133506B2 (en) * | 2008-03-12 | 2012-03-13 | Aptalis Pharmatech, Inc. | Drug delivery systems comprising weakly basic drugs and organic acids |
US20100080846A1 (en) * | 2008-09-25 | 2010-04-01 | Avshalom Ben-Menachem | Dipyridamole and acetylsalicylic acid formulations and process for preparing same |
KR20120022895A (ko) * | 2009-04-09 | 2012-03-12 | 엘커메스 파마 아일랜드 리미티드 | 약물 전달 조성물 |
US20110003005A1 (en) * | 2009-07-06 | 2011-01-06 | Gopi Venkatesh | Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions |
EP2361615A1 (en) | 2010-02-19 | 2011-08-31 | Alfred E. Tiefenbacher GmbH & Co. KG | Dipyridamole prolonged-release tablet |
EP3782614A1 (en) | 2013-10-07 | 2021-02-24 | Impax Laboratories, LLC | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
US10987313B2 (en) | 2013-10-07 | 2021-04-27 | Impax Laboratories, Llc | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
CN105640909B (zh) * | 2014-11-14 | 2019-09-20 | 正大天晴药业集团股份有限公司 | 一种含有达比加群酯的药用组合物 |
US11986449B2 (en) | 2020-12-22 | 2024-05-21 | Amneal Pharmaceuticals Llc | Levodopa dosing regimen |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2853420A (en) * | 1956-01-25 | 1958-09-23 | Lowey Hans | Ethyl cellulose coatings for shaped medicinal preparations |
US2928770A (en) * | 1958-11-28 | 1960-03-15 | Frank M Bardani | Sustained action pill |
US3081233A (en) * | 1960-08-08 | 1963-03-12 | Upjohn Co | Enteric-coated pilules |
US3247066A (en) * | 1962-09-12 | 1966-04-19 | Parke Davis & Co | Controlled release dosage form containing water-swellable beadlet |
NL297631A (es) * | 1963-06-03 | |||
US3538214A (en) * | 1969-04-22 | 1970-11-03 | Merck & Co Inc | Controlled release medicinal tablets |
DE2010416B2 (de) * | 1970-03-05 | 1979-03-29 | Hoechst Ag, 6000 Frankfurt | Oral anwendbare Arzneiform mit Retardwirkung |
DE2031871C3 (de) * | 1970-06-27 | 1974-06-27 | Roehm Gmbh, 6100 Darmstadt | Überzugsmasse für Arzneiformen |
US3954959A (en) * | 1973-03-28 | 1976-05-04 | A/S Alfred Benzon | Oral drug preparations |
GB1468172A (en) * | 1973-03-28 | 1977-03-23 | Benzon As Alfred | Oral drug preparations |
DE2336218C3 (de) * | 1973-07-17 | 1985-11-14 | Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz | Orale Arzneiform |
GB1479655A (en) | 1974-03-08 | 1977-07-13 | Beecham Group Ltd | Antibiotic preparations |
FR2353285A1 (fr) * | 1975-09-17 | 1977-12-30 | Doms Laboratoires | Medicament vasodilatateur coronarien perfectionne |
GB1576376A (en) * | 1977-03-30 | 1980-10-08 | Benzon As Alfred | Multiple-unit drug dose |
LU77353A1 (es) * | 1977-05-16 | 1979-01-19 | ||
DD146547A5 (de) | 1978-07-15 | 1981-02-18 | Boehringer Sohn Ingelheim | Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen |
CH647676A5 (fr) * | 1978-12-22 | 1985-02-15 | Donald E Panoz | Formes galeniques a usage oral, a liberation programmee et leurs procedes de preparation. |
-
1980
- 1980-01-12 DE DE19803000979 patent/DE3000979A1/de not_active Withdrawn
- 1980-12-12 IN IN896/DEL/80A patent/IN155158B/en unknown
- 1980-12-17 EP EP80107963A patent/EP0032562B1/de not_active Expired
- 1980-12-17 AT AT80107963T patent/ATE6585T1/de active
- 1980-12-17 DE DE8080107963T patent/DE3067058D1/de not_active Expired
- 1980-12-31 US US06/221,834 patent/US4367217A/en not_active Expired - Lifetime
-
1981
- 1981-01-09 PL PL1981229157A patent/PL129290B1/pl unknown
- 1981-01-09 GR GR63825A patent/GR73102B/el unknown
- 1981-01-09 IE IE40/81A patent/IE50807B1/en not_active IP Right Cessation
- 1981-01-09 CA CA000368242A patent/CA1148084A/en not_active Expired
- 1981-01-09 ES ES498393A patent/ES8207428A1/es not_active Expired
- 1981-01-09 FI FI810058A patent/FI78835C/fi not_active IP Right Cessation
- 1981-01-09 NO NO810061A patent/NO157369C/no not_active IP Right Cessation
- 1981-01-09 PT PT72330A patent/PT72330B/pt unknown
- 1981-01-09 YU YU39/81A patent/YU42549B/xx unknown
- 1981-01-09 IL IL61887A patent/IL61887A/xx not_active IP Right Cessation
- 1981-01-09 GB GB8100632A patent/GB2067073B/en not_active Expired
- 1981-01-09 NZ NZ195994A patent/NZ195994A/en unknown
- 1981-01-09 DK DK009481A patent/DK158539C/da not_active IP Right Cessation
- 1981-01-09 DD DD81226911A patent/DD156943A5/de not_active IP Right Cessation
- 1981-01-12 PH PH25080A patent/PH17063A/en unknown
- 1981-01-12 AR AR283919A patent/AR221983A1/es active
- 1981-01-12 JP JP303881A patent/JPS56103111A/ja active Granted
- 1981-01-12 OA OA57296A patent/OA06720A/xx unknown
- 1981-01-12 MA MA19241A patent/MA19040A1/fr unknown
- 1981-01-12 CS CS81232A patent/CS232713B2/cs unknown
- 1981-01-12 ZA ZA008101661A patent/ZA811661B/xx unknown
- 1981-01-12 AU AU66156/81A patent/AU539618B2/en not_active Expired
- 1981-01-12 HU HU8168A patent/HU184366B/hu unknown
-
1984
- 1984-04-04 SG SG281/84A patent/SG28184G/en unknown
- 1984-04-12 KE KE3402A patent/KE3402A/xx unknown
- 1984-08-09 HK HK621/84A patent/HK62184A/xx not_active IP Right Cessation
-
1985
- 1985-12-30 MY MY559/85A patent/MY8500559A/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES8207428A1 (es) | Procedimiento para la preparacion de una nueva forma de ac- cion retardada a base de dipiridamol | |
ES8400667A1 (es) | "procedimiento para la preparacion de una forma retardada debroxhexina, consistente en particulas esferoidales o tabletas dotadas de un recubrimiento". | |
DE3571393D1 (en) | Coating for pharmaceutical compositions | |
ES8304797A1 (es) | "procedimiento para la preparacion de nuevas formas orales de dipiridamol, en forma de granulados, pastillas o tabletas". | |
NO161257C (no) | Analogifremgangsm te for fremstilling av antiviralt aktive pyridazinaminer. | |
CA2171852A1 (en) | Budesonide pellets with a controlled release pattern and process for producing them | |
EP0339237A3 (en) | Phenol substituted gem-diphosphonate derivatives, process for their preparation and pharmaceutical compositions containing them | |
ES8404332A1 (es) | Procedimiento para preparar acidos omega-(1,4,5-trifenilimidazol-2-iloxi)-alcanicos | |
NO904621D0 (no) | Filmdannende bindemiddelsystem for anvendelse i tiksotrope beleggmaterialer, samt fremgangsmaate for fremstilling avet slikt bindemiddelsystem. | |
ES8106705A1 (es) | Procedimiento para la preparacion de derivados de aminoaci- dos | |
EP0393494A3 (en) | Bile acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them | |
ES8403494A1 (es) | "un procedimiento para la preparacion de derivados de s-adenosilmetionina". | |
IE42840L (en) | Flameproofing composition | |
ES8104235A1 (es) | Procedimiento para la preparacion de derivados de benzazepi-na | |
ES8502440A1 (es) | Procedimiento para preparar acepinoindoles. | |
Formby | The in vivo and in vitro effect of diphenylhydantoin and phenobarbitone on K+-activated phosphohydrolase and (Na+, K+)-activated ATPase in particulate membrane fractions from rat brain | |
PT83472A (en) | Process for preparing improved antiinflammatory compositions containing piroxicam | |
ATE44035T1 (de) | Derivate des neocarzinostatins und verfahren zu deren herstellung. | |
ES483087A1 (es) | Procedimiento para la obtencion de bencimidazolcarbamatos | |
JPS5441891A (en) | Adenine nucleotide derivative | |
NZ307053A (en) | Method for making quinolone carboxylic acids or naphthyridine carboxylic acids in free base form | |
GB1289039A (es) | ||
JPS525782A (en) | Preparation of 1-phthalazinone | |
KR830004842A (ko) | 디피리서다몰 서방출형 제제의 제조방법 | |
MA21434A1 (fr) | Procede de preparation de derives thieno-imidazole substitues utilisables comme inhibiteurs de la secretion d'acidite gastrique. |